Ensemble along with its partner Gatusso Development Partners are developing a 137,005 GSF class A build-to-suit office/lab building for Iovance Biotheraputics in the Philadelphia Navy Yard. The single-tenant building will be designed to meet the functional requirements of the client, while offering adaptability for future expansion. On-street and off-street parking will be available for use within close proximity to the building.
Iovance Biotherapeutic, a biopharmaceutical company, intends to accommodate production of their lead product – an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. The facility will include aseptic cell therapy manufacturing, analytical labs, training and process development rooms, and general office functions.